Evidence Hub

Non-genetic factors play more important role in lansoprazole metabolism than CYP2C19 pharmacogenetic profiles in European patients with burns

Mlčůchová N, Böhm J, Janošek J, Zendulka O, Gregorová J, Peš O, Fiamoli M, Lipový B et al.

Research Square, 2026

50 participants

Abstract

Abstract Single nucleotide variants in CYP2C19 gene, as well as some non-genetic factors, are associated with the effectiveness most proton pump inhibitors used for the stress ulcer prophylaxis and should be considered in personalized treatment. In this study, we aimed to determine the CYP2C19 *2 and *17 genotypes by qPCR and the concentration of lansoprazole and its metabolites using HPLC in 50 burn patients from European population on their first-ever lansoprazole prophylaxis. While CYP2C19 pharmacogenetic profiling in patients with burns played no significant role in predicting their ability to metabolize lansoprazole, association of non-genetic factors, such as age, sex, BMI, smoking, or substance abuse, with lansoprazole metabolism were detected. Our results suggest that when prescribing lansoprazole to prevent stress ulcers in burn patients from the European population, there is no particular need to take their genetic predispositions into consideration, as other factors have a greater effect.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free